WAVEMAN · COMPANY

BSX · Boston Scientific Corp

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

BSX

Name: BOSTON SCIENTIFIC CORP (BSX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BOSTON SCIENTIFIC CORP

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0000885725

CLUSTER · 5 INSIDERSC-SUITE BUYING · 1CONGRESS · 2☆ WATCH

INSIDER NET · 180D

$10.0M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

733

13F, latest reported quarter

REVENUE GROWTH

+19.9%

XBRL, annual

NET MARGIN

14.4%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$10.0M over 180 days

+$9.5M over 90 days

more than 98% of Medical Devices

CONGRESS

2 members bought in the last year

more than 81% of Medical Devices

FUNDS

733 funds added or opened last quarter

more than 95% of Medical Devices

REVENUE

+19.9% year over year

more than 76% of Medical Devices

MARGIN

14.4% net margin

more than 85% of Medical Devices

BUYBACKS

$2.0B repurchased, FY to 2026-06-30

more than 95% of Medical Devices

SHORT

1.5% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 69% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

5 insiders independently bought a net $10.0M while the stock fell 33% over six months — no planned sales are queued against it.

733 funds added or opened positions in the latest 13F quarter, of 1,480 holders.

2 members of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -55.2%

-55.2%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

5 insiders reported buying shares.

The record shows a net $10.0M bought by insiders over 180 days, 733 funds added last quarter, 2 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BOSTON SCIENTIFIC CORP insiders bought a net $10.0M of stock across 219 Form 4 purchases and sales, with 5 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Morano Susan E

Director

BUY

2026-08-25

2,040.0

$100.4K

Habiger David C

Director

BUY

2026-08-05

2,100.0

$99.9K

Habiger David C

Director

BUY

2026-08-04

140.0

$6.8K

Habiger David C

Director

BUY

2026-08-03

1,042.0

$50.1K

Mahoney Michael F

Chairman, President & CEO

BUY

2026-08-03

186,240.0

$9.0M

219 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 214 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

129,680,916.0 sh

$5.5B

VANGUARD CAPITAL MANAGEMENT LLC

97,087,553.0 sh

$4.1B

STATE STREET CORP

70,111,196.0 sh

$3.0B

PRIMECAP MANAGEMENT CO/CA/

50,520,914.0 sh

$2.2B

FMR LLC

45,702,845.0 sh

$2.0B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Select Medical Technology and Devices Portfolio

$449.6M POSITION · AS OF 2026-02-28

12.3%

Select Health Care Portfolio

$372.7M POSITION · AS OF 2026-02-28

6.0%

Goldman Sachs Future Health Care Equity ETF

$1.3M POSITION · AS OF 2026-02-28

5.8%

VIP Health Care Portfolio

$50.8M POSITION · AS OF 2026-03-31

5.1%

iShares U.S. Medical Devices ETF

$135.7M POSITION · AS OF 2026-03-31

4.3%

Fidelity Disruptive Medicine ETF

$2.5M POSITION · AS OF 2026-02-28

4.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 182 registered trials, 68 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Phase 2

1 ACTIVE

Phase 3

2 ACTIVE

Phase 4

1 ACTIVE

172

Not applicable

63 ACTIVE

What changed recently

LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston S

2026-09-04 · Active Not Recruiting → Completed

Not applicable

cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia

2026-09-03 · Recruiting → Active Not Recruiting

—

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Boston Scientific Corporation Political Action Committee (Bsc Pac)

CYCLE 2026 · $326K SPENT

$341.5K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Michael F. Mahoney

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$23.5M

$33.0M

$5.8M

+165%

+48%

2024

$21.4M

$65.8M

$5.5M

+148%

+29%

2023

$18.7M

$38.6M

$4.9M

+61%

+26%

2022

$16.9M

$21.6M

$4.9M

+29%

+24%

2021

$16.1M

$20.4M

$3.9M

+18%

+26%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$20.1B	$16.7B	$14.2B	$12.7B
GROSS PROFIT	$13.9B	$11.5B	$9.9B	$8.7B
OPERATING INCOME	$3.6B	$2.6B	$2.3B	$1.6B
NET INCOME	$2.9B	$1.8B	$1.6B	$698.0M
EPS (DILUTED)	1.94	1.25	1.07	0.45
OPERATING CASH FLOW	$4.5B	$3.4B	$2.5B	$1.5B
CASH	$2.0B	$414.0M	$865.0M	$928.0M
BUYBACKS	—	—	—	$0
DIVIDENDS PAID	—	$0	$28.0M	$55.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE